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Hormone control of total plasminogen activator activity is specific to
malignant DMBA-induced rat mammary tumours
K. Inada, J. Yamashita, S. Matsuo, Y. Nakashima, S. Yamashita & M. Ogawa
Second Department ofSurgery, Kumamoto University Medical School, Honjo, 1-1-1, Kumamoto 860, Japan.
Summary Hormonal regulation of plasminogen activator expression in 7,12-dimethylbenz[a]anthracene
(DMBA) - induced rat mammary carcinomas was studied both in vivo and in vitro and was compared to that
in DMBA-mammary dysplasia induced in neonatally androgenised rats. The plasminogen activator activity in
DMBA-mammary carcinomas, but not in DMBA-mammary dysplasia, was regulated by oestrogen. This
suggests that expression of this enzyme is hormonally regulated in carcinoma cells. Furthermore, in two of six
DMBA-mammary carcinoma groups classified in terms of hormonal treatment, plasminogen activator activity
was not under the control of oestrogen. Thus, the present results suggest that at the time ofcarcinogenesis, the
hormonal milieu determines the hormone sensitivities of the malignant cells.
The 7,12-dimethylbenz[a]anthracene (DMBA) - induced rat
mammary tumour model is valuable for studying the hor-
monal dependence of breast cancer in humans. In this model
system, several studies have provided evidence that the oes-
trogen receptor is present in breast cancer cells (King et al.,
1965; Mobbs, 1966). After Yoshida et al. (1978) revealed that
rat mammary dysplasia, which is morphologically similar to
its human counterpart, is induced in neonatally androgenised
rats (NA rats) by DMBA, this experimental model became
useful for investigations of neoplastic transformation. We
recently showed that in DMBA-induced rat mammary car-
cinomas and in the human breast cancer cell line, MCF-7,
the production of plasminogen activator is regulated by oes-
trogen via an oestrogen receptor system, and pointed out
that this enzyme can be a useful marker of oestrogen action
in breast cancer cells (Yamashita et al., 1984; Yamashita et
al., 1986). Moreover, we have confirmed that in contrast to
its effect on DMBA-carcinomas oestrogen has no effect on
plasminogen activator activity in the rat uterus (Inada et al.,
1991). We speculate, therefore, that oestrogen regulates the
cancer cell-specific gene expression of this enzyme. In the
present study, we studied this hypothesis by comparing the
effect of oestrogen on plasminogen activator production in
DMBA-induced rat mammary carcinomas to that in mam-
mary dysplasia induced in NA rats. We demonstrate that this
enzyme is produced specifically in DMBA-induced carcino-
mas and that this enzyme is not necessarily regulated by
oestrogen in some DMBA-induced carcinoma cells. We con-
clude that during carcinogenesis the hormonal milieu deter-
mines how plasminogen activator expression may be regulated
in transformed cells.
Materials and methods
Chemicals
The synthetic substrate S-2251 (H-D-Val-Leu-Lys-pNA),
human plasminogen, human plasmin and streptokinase were
purchased from Kabi Diagnostica, Stockholm. 17 beta-oes-
tradiol, progesterone, testosterone propionate, human melan-
oma t-PA, human urokinase, RNase and Triton X-100 were
obtained from Sigma Chemical Co., St Louis, MO. RPMI
1640 medium was purchased from GIBCO Laboratories,
Detroit, MI. Collagenase and DMBA were obtained from
Wako Pure Chemical Industries, Tokyo. The ER-EIA (enzyme
immunoassay) kits were purchased from the DAINABOT
Co., Ltd., Tokyo.
DMBA-induced mammary tumours
Newborn female Sprague-Dawley rats were divided into two
groups, a neonatally intact group and a neonatally andro-
genised group, designated as Groups I and II, respectively.
The rats belonging to Group II were neonatally androgenised
at 2 days of age by subcutaneous injection of 1.25 mg testos-
terone propionate in 0.05 ml of sesame oil, followed by one
of several types of endocrine manipulation, such as oopho-
rectomy and sex steroid administration. At 50 days of age,
each rat in both groups was fed a single 20 mg dose of
DMBA dissolved in 2 ml sesame oil. After DMBA-induced
rat mammary tumours had developed, tumour growth was
checked once weekly by measuring the two greatest dia-
meters. Four-8 weeks after the tumours were first detected,
the tumour-bearing rats were used for in vivo and in vitro
experiments. Tumour tissue was removed and stored immed-
iately at - 80°C before use. Histological examination of the
DMBA-induced rat mammary tumours was performed on
sections stained with haematoxylin and eosin.
Endocrine treatments
Each rat in Groups I and II was given 20 mg DMBA at 50
days of age and then each group was subdivided according to
the following endocrine treatment patterns (Figure 1):
Group I-a: 18 neonatally intact rats (NI rats) were given
no hormonal treatment.
Group I-b: 18 NI rats were oophorectomised via the pos-
terior approach at the same time they were
given DMBA.
Group II-a: 18 neonatally androgenised rats (NA rats)
were given no additional hormonal treatment.
Group II-b: 18 NA rats were subjected to oophorectomy
(OVX) at the same time they were given
DMBA.
Group Il-c: 16 NA rats were subjected to OVX at the
same time they were given DMBA and then
were given 10 fig oestradiol daily by intramus-
cular injection, starting at 28 days after
DMBA administration.
Group II-d: 22 NA rats were subjected to OVX at the
same time they were given DMBA and were
given 4 mg progesterone daily starting from
14 days before DMBA administration.
Group II-e: 24 NA rats were subjected to OVX at the
same time they were given DMBA and then
given 10 lg oestradiol and 4mg progesterone
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Figure 1 Endocrine treatment patterns. Each rat in Groups I
and II was given 20 mg DMBA at 50 days of age and then
subcategorised according to the endocrine treatment pattern. The
rats belonging to Group II were neonatally androgenised at 2
days of age by subcutaneous injection of 1.25 mg testosterone
propionate (TP) in 0.05 ml of sesame oil. This was followed by
one of several types of endocrine treatment, such as oophorec-
tomy (OVX), oestrogen (4+) and progesterone (t) administration.
The dotted lines indicate the periods after oophorectomy.
daily starting at 28 days after DMBA admin-
istration.
Group II-f: 22 NA rats were subjected to OVX at 28 days
after DMBA administration and then given
4 mg progesterone daily starting on the same
day as OVX.
Group II-g: 16 NA rats were given 4mg progesterone
daily starting 28 days after DMBA was given
without OVX.
Group II-h: 16 NA rats were given 4mg progesterone
daily from 14 days before DMBA administra-
tion until the day of DMBA administration
without OVX.
Except for the rats in Group IT-h, hormonal injections were
continued until the end of the experiments.
Assayforplasminogen activator
Frozen tissue from each DMBA-tumour was homogenised
and extracted with 50 mM Tris-HCI buffer (pH 7.4) contain-
ing 0.25% Triton X-100, as described previously (Yamashita
et al., 1984; Yamashita et al., 1986). Plasminogen activator
activity was determined according to the method of Thorsen
(1982) except that 0.76 mM S-2251 was employed as a sub-
strate. One unit of the enzyme was defined as the amount of
enzyme required to increase the optical density by 0.08 absor-
bance units in 2 h at 37°C. This unit corresponds to the
International Unit (IU) employed to express streptokinase
activity. Specific activity is expressed as units mg-' protein.
Protein concentrations were determined by the method of
Bradford, using bovine serum albumin as the standard (Brad-
ford, 1976). The amount of plasmin inhibitor in the DMBA-
tumour extracts was determined by the method of Shimada
et al. (1981) except that the reaction mixture contained
bovine serum albumin (0.5 mg ml-'). No activity was detect-
ed in the tumour extracts, confirming that under the present
assay conditions all hydrolytic activity in the tumour extracts
was due to plasminogen activator.
Assayfor oestrogen receptor
In each DMBA-induced rat mammary tumour in each group
examined in the present study, oestrogen receptors were
quantitated by the enzyme immunoassay method (Greene &
Jensen, 1982). Oestrogen receptors were deemed to be present
at > 10 fmol receptormg-' protein.
In vivo experiments
The DMBA-tumour-bearing rats in Groups I-a and II-a were
used for in vivo experiments. Four weeks after the tumours
were first detected, the tumour-bearing rats were oophorec-
tomised. One weekly after OVX, each rat was given a single
subcutaneous dose of oestradiol (10 ytg in 10% ethanol
solution/lOOg body weight). DMBA-induced tumours were
removed under ether anesthesia at 4 h intervals up to 20 h
after oestradiol administration. The plasminogen activator
activity in each DMBA-induced tumour was assayed as
described above.
In vitro experiments
Primary cultures of DMBA-mammary tumour cells were
initiated and maintained as described previously (Yamashita
et al., 1984). When the cells were nearly confluent, the culture
medium in each flask was replaced with a serum-free medium
by washing with RPMI medium. Each culture was then
incubated further for 3 days at 37°C in the serum-free
medium prior to adding either oestradiol or the vehicle.
Oestradiol dissolved in 0.1% ethanol was added to yield a
final concentration of 10-8 M. Aliquots of culture medium
taken at the indicated times were centrifuged at 800g for
10min at 4°C. The resulting supernatants were assayed for
plasminogen activator activity as described above.
Assayforplasminogen activator inhibitor (PAI) activity
To clarify whether or not PAI are involved in the hormonal
regulation of plasminogen activator in DMBA-tumours, PAI
acivity was determined by titrating the tumour extracts or the
conditioned medium with human melanoma t-PA or human
urokinase and then determining by spectrophotometry the
residual plasminogen activator activity, as described (Ver-
heien et al., 1984). The PAI activity was negligible in each
tumour examined in the in vivo experiments and in every
supernatant in the in vitro experiments. This suggests that
plasminogen activator activity in these samples was modu-
lated directly by a hormone.
Statistical analysis
The statistical significance of any difference in plasminogen
activator activity and oestrogen receptor content was deter-
mined by Student's t test. The X2 test was used to assess the
statistical significance of differences in the incidence or the %
diploidy of DMBA-induced mammary tumours in each group.
Results
Effects ofsex steroids on DMBA-induced mammary tumours
Three types of palpable mass were found in the mammary
glands: mammary carcinomas, grossly visible cysts, and
mammary dysplasia (regarded to be a benign lesion). The
cystic nodules were soft and filled with a milky fluid, and
were identified microscopically as epithelial cysts. Mammary
dysplasia was characterised by heterogenous microscopic
features including adenosis, fibrosis, duct papillomatosis and
fibroadenoma-like lesions. It was difficult to distinguish by
palpation mammary carcinomas from nodules. The most
common type of mammary dysplasia is adenosis. Therefore,
we used this histological type of dysplasia in both in vivo and
in vitro experiments.
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The effects of hormonal manipulation on DMBA-induced
mammary tumours in rats are summarised in Table I. When
20 mg of DMBA was fed to the NI rats (Group I-a), 100%
of the animals developed mammary carcinomas within 50-
120 days, and oophorectomy performed simultaneously with
DMBA administration prevented completely tumour induc-
tion (Group I-b).
Mammary tumours with the microscopic characteristics of
dysplasia were induced in 88.9% of the NA rats (Group II-a)
and the development of palpable carcinomas in this group
was completely suppressed. In NA rats with OVX + P
(Groups II-d and TI-f) and with OVX + E + P (Group II-e),
the number of rats with palpable carcinomas increased signi-
ficantly (P<0.001), as compared to NA rats (Groups IT-a),
NA rats with OVX (Group 11-b), or NA rats with OVX + E
(Group TI-c). Furthermore, the incidence of DMBA-induced
mamary carcinoma was higher in NA rats with P (Groups
II-g and IT-h) than in NA rats with OVX + P (Groups II-d
and II-f) or with OVX + E + P (Group II-e) (P<0.001).
Plasminogen activator activity in DMBA-induced rat
mammary tumours
Table II shows the plasminogen activator activity in DMBA-
induced rat mammary tumours in each group. The enzyme
activity was significantly higher in DMBA-induced carcino-
mas than in dysplasia. Lower activity was found in the II-d
and IT-f carcinoma groups than in the other carcinoma
groups.
In vivo effects ofoophorectomy and oestrogen administration
on plasminogen activator activity ofDMBA-induced rat
mammary carcinomas and dysplasia
As shown in Figure 2, the plasminogen activator activity of
DMBA-induced rat mammary carcinomas was under the
control of oestradiol in vivo. The plasminogen activator
activity was 577 units mg-' protein. Within a week after
oophorectomy, the activity decreased to less than 7% of
baseline (37 units mg-' protein). After administering oestra-
diol to the oophorectomised tumour-bearing rats, the plas-
minogen activator activity of the tumours increased to reach
a maximum of 376 units mg-' protein after 12 h. This was
followed by a gradual decrease to 214 units mg-' protein at
20h.
DMBA-induced dysplasia displayed significantly lower
plasminogen activator activity (68 units mg-' protein) than
did DMBA-induced carcinomas. Furthermore, in sharp con-
trast to the carcinomas, the enzyme activity in dysplasia did
change appreciably after oophorectomy or oestradiol admini-
stration.
In vitro effects ofoestrogen on plasminogen activator activity
in DMBA-induced rat mammary carcinomas and dysplasia
We examined the effects of oestrogen on plasminogen acti-
vator activity in primary cultures of DMBA-induced rat
mammary tumour cells in each group. As shown in Figure 3,
enzyme activity in the culture medium of group I-a car-
cinoma cells increased markedly in the presence of 10-8 M
oestradiol, a concentration equivalent to the physiological
level.
Furthermore, DMBA-induced rat mammary carcinoma
cells in Groups II-e, II-g and II-h showed a similar oestrogen
Table I Effects of sex steroids on induction of DMBA-induced rat
mammary tumours
Group and treatmenta
I-a: NIC
I-b: NI + OVXe
IT-a: NAd
IT-b: NA + OVXe
TI-c: NA + OVXe + Eg
II-d: NA + OVXe + ph
11-e: NA + OVXe + Eg + Pi
TI-f: NA + OVX' + Pi
II-g: NA + Pi
II-h: NA + Pi
No. of
rats in
group
18
18
18
18
16
22
24
22
16
16
No. of rats
with palpable
carcinomas
(%)b
18 (100.0)
0 (O)k
0 (O)k
0 (0)
0 (0)
6 (27.3)m..
5 (20.8)
4 (18.2)
14 (87.5)1.0
11 (68.8)'
No ofrats
with mammary
dysplasia
(%)b
0 (0)
0 (0)
16 (88.9)k
0 (0)'
0 (0)'
0 (0)'
0 (0)'
1 (4.5)'
14 (87.5)
10 (62.5)
aAt 50 days ofage, 20 mg DMBA was given to rats in every group by
gastric intubation. bWhen more than one tumour developed in each
animal, all tumours were examined. In the II-g and IT-h groups, both
carcinoma and dysplasia co-existed in several rats. CNI = Neonatally
Intact Rats. dNA = Neonatally Androgenised rats; 1.25 mg testos-
teronepropionate was given by s.c. injection at 2daysofage. eovXwas
performed at the same time as DMBA administration. 'OVX was
performed at 28 daysafter DMBA administration.gIOjg E (oestradiol)
was given daily by i.m. injection starting from 28 days after DMBA
administration. h4 mg P (progesterone) was given daily by i.m. injection
starting 14 days before DMBA administration. '4 mg P was given daily
by i.m. injection starting 28 days after DMBA administration. J4 mg P
was given daily by i.m. injection from 14 days before DMBA adminis-
tration until the day of DMBA administration. kDiffers from I-a;
P<0.001. 'Differs from IT-a; P<0.001. mDiffers from TI-a; P<0.05.
nDiffers from TI-b; P<0.05. °Differs from II-f; P<0.001.
dependency of enzyme production. Since DMBA-induced rat
mammary dysplasia (Groups II-a, II-g and II-h) showed no
apparent increase in plasminogen activator activity on oestra-
diol administration, the hormonal regulation of this enzyme
was considered to be specific to carcinoma cells. However, an
exceptional result was obtained in an in vitro experiment with
DMBA-induced rat mammary carcinoma cells from Groups
II-d and II-f. These cells displayed no appreciable change in
plasminogen activator activity, regardless of the presence or
absence of oestradiol.
Oestrogen receptor in DMBA-tumours
Table III shows the oestrogen receptor content of DMBA-
induced rat mammary tumours in each group. The results
confirm that each tumour examined in the present study was
oestrogen receptor-positive and there were no significant
difference in the oestrogen receptor content among the
tumours in each group.
Discussion
There have been only a few reports of the relationship
between progesterone and DMBA-mammary carcinogenesis
(McCormick & Moon, 1965; Jabara et al., 1973; Nagasawa
et al., 1986). Since complicated interactions are observed at
the cellular level among several hormones, such as oestrogen,
progesterone and prolactin (Nagasawa & Morii, 1981), it is
difficult to specify the hormonal environment in the present
Table II Plasminogen activator activity in DMBA-induced rat mammary tumours
Group
Dysplasia Carcinomas
II-a II-g II-h I-a II-d II-e II-f II-g II-h
PA activitya 68±20b,c 62±24c 70±23C 577± 128 251±73d 641 ± 170 198±48d 548±144 517± 128
(mean±s.d.) (12) (10) (10) (12) (10) (8) (8) (10) (10)
aPA activity; plasminogen activator activity (units mg-' protein). bNumbers in parentheses are the numbers of
tumours examined. CDiffers from carcinoma groups; P<0.001; dDiffers from the other carcinoma groups; P<0.001.PLASMINOGEN ACTIVATOR IN DMBA-INDUCED TUMOUR 581
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Figure 2 In vivo effects of oophorectomy and subsequent oest-
radiol administration on plasminogen activator activity in
DMBA-tumours (0, mammary carcinomas in Group I-a; 0,
mammary dysplasia in Group IT-a). One week after oophorec-
tomy, each DMBA-tumour bearing rat was given by sub-
cutaneous injection a single dose of oestradiol (10 1tg/100 g body
weight). Tumours were removed at 4 h intervals up to 20 h and
assayed for plasminogen activator activity as described under
Materials and methods. Solid bars indicate the standard devia-
tion of plasminogen activator activity and n denotes the number
of animals tested. During the first week following oophorectomy,
28 mammary carcinoma tumours remained static and 14 of these
regressed slightly, while all 42 mammary dysplasia tumours
remained static.
experimental rats. According to earlier reports, however, the
levels of serum prolactin and oestrogen in NA rats seem to
be within normal range and similar to that in NI rats. The
serum progesterone level is, however, much lower in NA rats,
all of the corpora lutea being absent in the ovaries, than in
NI rats (Yoshida et al., 1980; Cristakos et al., 1976). The
results obtained in the present investigation show that
supplementation with progesterone in NA rats increases
significantly the incidence of DMBA-induced rat mammary
carcinoma. This effect is enhanced further by the co-admini-
stration of oestrogen (Table I). Yoshida et al. (1978, 1980)
found, in a detailed study using NA rats, that progesterone
promotes mammary carcinogenesis during the growth phase
of dysplastic mammary cells. Their experiment was, however,
different from ours in the time of oophorectomy and the
timing of sex steroid administration. In the present study, we
obtained similar results, indicating that progesterone stim-
ulates the growth of DMBA-mammary carcinomas which
have already been induced.
Plasminogen activators are serine proteases which convert
the inactive zymogen, plasminogen, to the protease, plasmin,
a principal enzyme involved in fibrinolysis. Since plasmin-
ogen activators are produced by a wide variety of tumour
cells, several authors have suggested that the activators can
be used as markers of malignant change (Howett et al., 1978;
Unkeless et al., 1975; Duffy & O'Grady, 1984; Soumendra &
Rajeswari, 1987; Butler et al., 1986). Our in vivo and in vitro
experiments demonstrate clearly that plasminogen activator
activity in DMBA-induced rat mammary carcinomas is con-
trolled by oestrogen. In contrast, oestrogen induction of this
enzyme was not observed in DMBA-induced rat mammary
dysplasia. We previously reported that oestrogen does not
have any effect on plasminogen activator activity in either the
normal rat uterus or normal breast tissue (Inada et al., 1991)
but our present data comprise the first evidence that the
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Figure 3 In vitro effects of oestrogen on plasminogen activator
production. Cultures of DMBA-induced mammary carcinoma
cells (Groups I-a, II-d, II-e, TI-f, 1I-g and 11-h) and mammary
dysplasia cells (Groups II-a, 11-g and IT-h) were plated in 25-cm2
T-flasks and then incubated for 3 days in a serum-free medium
prior to the experiments. After adding 10-8 M oestradiol (0) or
the vehicle (0), aliquots of the culture medium were withdrawn
at the indicated times and assayed for plasminogen activator
activity as described under Materials and methods. Each point
represents the mean value of four individual experiments.
Table III Oestrogen receptor contents of DMBA-induced rat mam-
mary tumours
Oestrogen receptor content
Group fmolmg-' protein (mean±s.d.)
Dysplasia II-a 27.6+ 16.9 (7)a
II-g 31.3+ 18.3 (7)
IT-h 28.2± 17.5 (7)
Carcinomas I-a 43.4± 22.0 (7)
11-d 27.4± 15.9 (5)
TT-e 40.0±28.0 (5)
II-f 28.8± 18.1 (5)
II-g 40.2± 24.0 (7)
TI-h 24.2± 12.1 (7)
aNumbers in parentheses are the numbers of tumours examined.
There is no statistically significant difference in the oestrogen receptor
contents of DMBA-tumours among the groups.
oestrogen dependence of plasminogen activator is acquired
during the process of malignant transformation of rat mam-
mary cells.
Conflicting data on the oestrogen dependence of the enzyme
were obtained for Groups II-d and II-f carcinoma cells in
vitro. Primary cultures of these carcinoma cells did not
exhibit an oestraogen-dependent increase in plasminogen
activator. Although every DMBA-induced rat mammary car-
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cinomas examined in the present study was confirmed to be
oestrogen receptor-positive, with similar contents, the recep-
tors of the mammary carcinoma cells in Groups II-d and 1I-f
are considered to be non-functional. One explanation would
be that an intact ovary is required to see oestrogen effects in
culture and oestrogen preconditioning in vivo is required to
get in vitro effects. Thus, these findings support the possibility
that during carcinogenesis a hormonal difference contributes
to the difference seen in the biologic characteristics of mam-
mary carcinomas, such as the oestrogen dependency of plas-
minogen activator expression. To our knowledge, there has
been no report to date ofany significant relationship between
hormonal control of plasminogen activator in DMBA-induc-
ed rat mammary tumours and the hormonal milieu during
neoplastic transformation.
DMBA-mammary tumours are prolactin dependent. High
plasma levels of this hormone favor the development and
subsequent growth of a mammary tumour, even in oophorec-
tomised rats. A similar phenomenon observed upon the
administration of oestrogen may be due to its stimulating
prolactin secretion by the pituitary. This view was also sup-
ported by the finding that oestrogen has little effect on the
growth of DMBA-mammary tumours in hypophysectomised
rats. However, data which support the direct involvement of
oestrogen are also available, in that in rats bearing DMBA-
mammary tumour and in which the hypothalamus had been
destroyed, oophorectomy results in a rapid regression of
tumours even while a high plasma levels of prolactin is
maintained. It is difficult to specify whether in the present
study the in vivo oestrogen dependency of DMBA-carcinoma
is direct or indirect. However, the results of the in vitro
studies of DMBA-induced carcinoma cells in primary culture
(I-a, II-e, II-g and II-h) suggest strongly that oestrogen exerts
its function directly. Taken together, our present data indi-
cate that the hormonal milieu dictates the DMBA-induced
tumour's hormone sensitivity and that in some of the result-
ing tumours, oestrogen exerts its effect directly by a route
distinct from the prolactin pathway.
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